OA11325A - Process for preparing growth hormone secretagogues. - Google Patents

Process for preparing growth hormone secretagogues. Download PDF

Info

Publication number
OA11325A
OA11325A OA1200000050A OA1200000050A OA11325A OA 11325 A OA11325 A OA 11325A OA 1200000050 A OA1200000050 A OA 1200000050A OA 1200000050 A OA1200000050 A OA 1200000050A OA 11325 A OA11325 A OA 11325A
Authority
OA
OAPI
Prior art keywords
formula
compound
oxo
methyl
pyridin
Prior art date
Application number
OA1200000050A
Other languages
English (en)
Inventor
Frank Robert Busch
Charles Kwok-Fung Chiu
Clifford Nathaniel Meltz
Ronald James Post
Peter Robert Rose
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11325A publication Critical patent/OA11325A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
OA1200000050A 1999-02-26 2000-02-23 Process for preparing growth hormone secretagogues. OA11325A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12274599P 1999-02-26 1999-02-26

Publications (1)

Publication Number Publication Date
OA11325A true OA11325A (en) 2003-10-27

Family

ID=22404505

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000050A OA11325A (en) 1999-02-26 2000-02-23 Process for preparing growth hormone secretagogues.

Country Status (44)

Country Link
US (2) US6541634B2 (bg)
EP (2) EP1031575B1 (bg)
JP (3) JP3437813B2 (bg)
KR (2) KR100372063B1 (bg)
CN (3) CN1137891C (bg)
AP (1) AP1221A (bg)
AR (2) AR029617A1 (bg)
AT (1) ATE277944T1 (bg)
AU (1) AU764122B2 (bg)
BG (1) BG104175A (bg)
BR (2) BRPI0000967B8 (bg)
CA (1) CA2299495C (bg)
CO (1) CO5160252A1 (bg)
DE (1) DE60014212T2 (bg)
DK (1) DK1031575T3 (bg)
DZ (1) DZ3018A1 (bg)
EA (1) EA003218B1 (bg)
EE (1) EE200000193A (bg)
ES (1) ES2226712T3 (bg)
GT (1) GT200000018A (bg)
HK (1) HK1030219A1 (bg)
HN (1) HN2000000021A (bg)
HR (1) HRP20000103A2 (bg)
HU (1) HUP0000907A3 (bg)
ID (1) ID24861A (bg)
IL (2) IL134599A (bg)
IN (1) IN192352B (bg)
IS (1) IS5380A (bg)
MA (1) MA25072A1 (bg)
NO (1) NO20000965L (bg)
NZ (1) NZ503062A (bg)
OA (1) OA11325A (bg)
PA (1) PA8491201A1 (bg)
PE (1) PE20001550A1 (bg)
PL (1) PL338628A1 (bg)
PT (1) PT1031575E (bg)
SG (1) SG90096A1 (bg)
SI (1) SI1031575T1 (bg)
SK (1) SK284982B6 (bg)
TN (1) TNSN00035A1 (bg)
TR (1) TR200000536A2 (bg)
TW (2) TWI286142B (bg)
UA (1) UA70306C2 (bg)
ZA (1) ZA200000888B (bg)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
AU6497701A (en) 2000-05-30 2001-12-11 Merck & Co Inc Melanocortin receptor agonists
WO2004103983A1 (en) * 2003-05-26 2004-12-02 Biocon Limited Process for the preparation of s(+)-2-ethoxy-4-[n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl]benzoic acid derivatives
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US9117477B2 (en) 2013-05-08 2015-08-25 HGST Netherlands B.V. Perpendicular magnetic recording media having novel seed layer
WO2014192294A1 (en) * 2013-05-28 2014-12-04 Raqualia Pharma Inc. Polymorph forms
CN109320515A (zh) * 2018-11-22 2019-02-12 常州大学 一种Capromorelin手性中间体的不对称合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
CZ134296A3 (en) 1993-11-09 1996-12-11 Merck & Co Inc Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof
US5609150A (en) 1995-04-18 1997-03-11 Maged; Jeffrey M. Method for dilating respiratory passages
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2334097A (en) 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
WO1997036873A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
AU7445498A (en) 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)

Also Published As

Publication number Publication date
CO5160252A1 (es) 2002-05-30
IL134599A (en) 2006-12-10
HUP0000907A2 (en) 2001-03-28
MA25072A1 (fr) 2000-10-01
IL157103A (en) 2007-07-24
UA70306C2 (en) 2004-10-15
EP1449842A1 (en) 2004-08-25
IN192352B (bg) 2004-04-10
IS5380A (is) 2000-08-27
CN1837205A (zh) 2006-09-27
GT200000018A (es) 2001-08-16
KR20020065455A (ko) 2002-08-13
JP2003261565A (ja) 2003-09-19
TWI286142B (en) 2007-09-01
KR100361783B1 (ko) 2002-11-22
JP4051314B2 (ja) 2008-02-20
ES2226712T3 (es) 2005-04-01
SK284982B6 (sk) 2006-03-02
EA200000172A3 (ru) 2000-10-30
KR20010006698A (ko) 2001-01-26
US6541634B2 (en) 2003-04-01
BRPI0017522A2 (bg) 2009-12-22
CA2299495C (en) 2010-06-15
SG90096A1 (en) 2002-07-23
PE20001550A1 (es) 2001-01-11
BRPI0000967B1 (pt) 2012-06-12
JP3437813B2 (ja) 2003-08-18
US20030158414A1 (en) 2003-08-21
HK1030219A1 (en) 2001-04-27
PL338628A1 (en) 2000-08-28
CA2299495A1 (en) 2000-08-26
TW200718702A (en) 2007-05-16
DE60014212T2 (de) 2005-12-15
ATE277944T1 (de) 2004-10-15
AR053722A2 (es) 2007-05-16
TNSN00035A1 (fr) 2005-11-10
BRPI0017522B8 (pt) 2021-05-25
ID24861A (id) 2000-08-31
AP2000001754A0 (en) 2000-03-31
US20020002283A1 (en) 2002-01-03
US6673929B2 (en) 2004-01-06
PT1031575E (pt) 2004-11-30
SK2302000A3 (en) 2000-11-07
BG104175A (bg) 2000-12-29
AP1221A (en) 2003-11-03
IL134599A0 (en) 2001-04-30
DK1031575T3 (da) 2005-01-03
ZA200000888B (en) 2001-08-23
BRPI0017522B1 (pt) 2013-09-24
CN1270960A (zh) 2000-10-25
TR200000536A2 (tr) 2000-09-21
EE200000193A (et) 2000-10-16
EP1031575B1 (en) 2004-09-29
IL157103A0 (en) 2004-02-08
AU764122B2 (en) 2003-08-07
DE60014212D1 (de) 2004-11-04
NZ503062A (en) 2001-07-27
EP1031575A1 (en) 2000-08-30
KR100372063B1 (ko) 2003-02-14
CN1515570A (zh) 2004-07-28
HN2000000021A (es) 2001-02-02
AR029617A1 (es) 2003-07-10
HUP0000907A3 (en) 2001-05-28
JP2000247974A (ja) 2000-09-12
HU0000907D0 (en) 2000-04-28
PA8491201A1 (es) 2001-04-30
AU1947100A (en) 2000-08-31
BRPI0000967A (pt) 2001-09-11
SI1031575T1 (en) 2005-02-28
JP2003327585A (ja) 2003-11-19
EA200000172A2 (ru) 2000-08-28
CN1137891C (zh) 2004-02-11
NO20000965D0 (no) 2000-02-25
HRP20000103A2 (en) 2001-04-30
NO20000965L (no) 2000-08-28
DZ3018A1 (fr) 2004-03-20
EA003218B1 (ru) 2003-02-27
BRPI0000967B8 (pt) 2021-12-07

Similar Documents

Publication Publication Date Title
CA2968176C (en) Cgrp receptor antagonists
ES2922029T3 (es) Análogos de hexahidropirimidina antimalaria
TW200813094A (en) Compounds and compositions as channel activating protease inhibitors
KR20170137725A (ko) 데스아세톡시투불리신 h 및 이의 유사체
OA11325A (en) Process for preparing growth hormone secretagogues.
KR20190044652A (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
CA2892368A1 (en) Ketoamide immunoproteasome inhibitors
CN115190882A (zh) 通过共同中间体有效制备多拉司他汀和奥里斯他汀类似物
US5463124A (en) Process for the diastereoselective reductive pinacol coupling of homochiral α-aminoaldehydes
WO2024017880A1 (en) Imidazotriazine derivatives as il-17 modulators
AU738462B2 (en) Process for the synthesis of chloropurine intermediates
JP2008518883A (ja) タンパク質キナーゼ阻害剤として有用な6−(2−アルキル−フェニル)−ピリド[2,3−d]ピリミジン
US5519113A (en) Process for the diastereoselective reductive pinacol coupling of homochiral α-aminoaldehydes
SG192948A1 (en) Peptide deformylase inhibitors
CZ2000704A3 (cs) Způsob přípravy sloučenin podporujících sekreci růstového hormonu
KR101691353B1 (ko) 보르테조밉의 제조방법 및 그의 신규 중간체
US20050096466A1 (en) Process for the preparation of tetrazol-derived compounds as growth hormone secretagogues
WO2019168025A1 (ja) モルヒナン誘導体の製造方法
MXPA00002031A (en) Process for preparing growth hormone secretagogues